Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. John Manolis Athanasios
Hypertension will continue to be a major risk factor for cardiovascular, renal and other complications and its prevalence will be of 1.56 billion in the next years. There are many reasons a) the targets of blood pressure are reached by only 20-30% of patients, b) the other coexisting risk factors that may increase the prevalence of hypertension are increasing rapidly. Can intervention in early stages (ie prehypertension) prevent hypertension? It is difficult to answer this question, however there are some data showing that the use of some classes of antihypertensive drugs may delay the appearance of the disease in pre-hypertensive patients. However, in pre-hypertensive patients and mainly in those with multiple risk factors the most important preventive measure is life style modifications. So, is non-pharmacological treatment effective? Life style changes such as weight reduction, salt restriction, exercise etc. may decrease blood pressure by 2-10 mm Hg. The main problem is the compliance of the patients because their majority will stop the non-pharmacologic interventions in less than six months. What is the future of antihypertensive treatment? For sure, the larger the number of therapeutic options, the better the blood pressure control. However, because there are only five drug classes for first line treatment, the previous, but also the upcoming ESH/ESC guidelines will help doctors to select the right drug class for the right patient, the right condition. Finally, it is important to remember that most patients need combination treatment and our goal is to find the right combination in accordance with the presence of risk factors, subclinical and clinical organ damage.
A world with 1.56 billion hypertensives in 2025